Form 4: Elanco Animal Health Exec Reports Stock Unit Transaction

Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc., reported a transaction involving deferred stock units.

Summary

• Jeffrey N. Simmons, who holds the positions of President, CEO, and Director at Elanco Animal Health Inc., has reported a transaction.
• The transaction involved 123.8795 deferred stock units.
• These units represent the right to receive one share of Elanco's common stock or its cash equivalent.
• The transaction date was April 3, 2026.
• The deferred stock units are set to settle in cash or shares of common stock upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.
• Following this transaction, Mr. Simmons beneficially owns 23,919.1498 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine reporting of executive stock unit transactions rather than a significant strategic or financial event.

Positives

• The reporting person, a key executive and director, is actively participating in the company's stock plans.
• The transaction indicates continued alignment of executive interests with shareholder value through stock ownership.

Negatives

• The filing does not provide details on the specific price at which the deferred stock units were acquired or their current market value at the time of reporting, beyond the implied value of $22.82 per share for the settlement.

Risks

• The value of the deferred stock units is subject to fluctuations in Elanco Animal Health Inc.'s common stock price.
• The settlement of these units is contingent upon future events such as termination of employment or a specified future year.

Future Outlook

Deferred stock units are set to settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with the Executive Deferral and Stock Match Plan.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions in publicly traded companies, reflecting executive participation in equity-based compensation plans, which is common across the animal health industry.

Stakeholder Impact

• Shareholders: The transaction reflects executive participation in company stock plans, which can influence alignment of interests. The settlement of units will impact the number of outstanding shares or cash reserves.
• Employees: The Executive Deferral and Stock Match Plan, under which these units were granted, is a component of the company's overall compensation strategy for executives.
• Management: The reporting person, as CEO and Director, is subject to these reporting requirements, ensuring transparency in ownership changes.

Next Steps

• Settlement of deferred stock units in cash or shares upon termination of employment or during a specified future year.

Key Dates

Keywords

Elanco Animal Health, Form 4, SEC Filing, Stock Transaction, Deferred Stock Units, Executive Compensation, Beneficial Ownership, Jeffrey N. Simmons, ELAN